The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 ...

Suzetrigine and the Promise of Non-Opioid Pain Relief. At the forefront of Vertex's expansion into pain management is suzetrigine (VX-548), a novel drug candidate with the potential to ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug ...

Vertex has a strong pain management pipeline, which is likely to help the company emerge as one of the largest players in this market. Exhibit 2: Vertex's pain management drug pipeline.

Vertex's stock has risen 18% since last December, ... to believe VK-548's potential in neuropathies is more interesting than its potential in a crowded and complex acute pain management market.

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, ... A Promising Non-Opioid Solution to Acute Pain Management. TipRanks. Oct. 21, 2024, 04:55 AM.

Acute pain is something more than 80 million Americans fill prescriptions to treat each year, according to Vertex. As opposed to chronic pain, which can last well after an injury or illness has ...

Leerink Partners analyst David Risinger maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $600.00. David Risinger has given his Buy ...

If Vertex does get payer buy-in, Journavx could be an exception to a longstanding, unwritten rule in pain management: fresh therapies take a while to reach patients.

Vertex is strategically expanding into the pain management sector, Vertex Pharmaceuticals (NASDAQ:VRTX) is a biotechnology company with a strong track record of success in developing treatments ...